Abeona Therapeutics Inc（ABEO）の財務ABEOAbeona Therapeutics Inc

Evaluating the bottom line, Abeona Therapeutics Inc maintains a gross margin of 63.30%. This metric reflects the company's pricing power and manufacturing efficiency. Further down the income statement, the operating margin stands at -119.97%, while the net margin is -177.43%. These profitability ratios, combined with a Return on Equity (ROE) of -43.13%, provide a clear picture of how effectively ABEO converts its operational activities into shareholder value.

In the context of the broader market, ABEO competes directly with industry leaders such as FULC and VNDA. With a market capitalization of $249.32M, it holds a significant position in the sector. When comparing efficiency, ABEO's gross margin of 63.30% stands against FULC's N/A and VNDA's 89.02%. Such benchmarking helps identify whether Abeona Therapeutics Inc is trading at a premium or discount relative to its financial performance.

Abeona's revenue for Q2 2026 was 11,380,000 USD, with a gross margin of 63.30%. However, the company reported a net income loss of -20,191,000 USD for the same quarter, reflecting ongoing financial challenges.